## CONCLUSION

In view of the foregoing amendments and comments, it is respectfully submitted that the present application is fully in condition for allowance, and such action is earnestly solicited.

The undersigned had made a good faith effort to place the claims in condition for immediate allowance. Nevertheless, if any undeveloped issues remain or if any issues require clarification, the Examiner is respectfully requested to call the undersigned in order to resolve such issue promptly.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 15 Mar. 2001

By: Daniel Altman

Daniel E. Altman
Registration No. 34,115
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660

CCT-1171.DOC:CB031401

## VERSION WITH MARKINGS TO SHOW CHANGES MADE

**[CLAIMS]** WHAT IS CLAIMED IS:

1. (Amended) A method for the prophylaxis or treatment of an airway disease condition in an animal, said method comprising administering to said animal, an effective amount of an agent capable of activating an airway epithelium protease activated receptor (PAR) for a time and wherein under conditions sufficient for activation of said PAR to occur, **[wherein]** the activated PAR stimulates, induces or otherwise facilitates inhibition of bronchoconstriction and/or inflammation.

2. (Amended) **[A]** The method according to claim 1 wherein the animal is a human.

3. (Amended) **[A]** The method according to claim 1 **[or 2]** wherein the PAR is a receptor selected from the group consisting of PAR1 **[or]** and PAR2.

4. (Amended) **[A]** The method according to claim 3 wherein the PAR is PAR2.

5. (Amended) **[A]** The method according to claim **[3]** 1 wherein the ariway disease condition is a disease selected from the group consisting of asthma, bronchitis, hayfever, alveolitis, ciliary dyskinesis **[or]** and pulmonary inflammation.

6. (Amended) **[A]** The method according to claim 3 wherein the agent is a peptide selected from the group consisting of <400>1, <400>2 and <400>3 or functional equivalents, homologues or derivatives thereof.

7. (Amended) **[A]** The method according to claim 6 wherein the peptide is modified to permit entry across an epithelial and/or subcutaneous layer.

8. (Amended) **[A]** The method according to claim 7 wherein the peptide is fused to penetratin.

9. (Amended) **[A]** The method according to claim 7 wherein the peptide is fused to TAT or a functional derivative or homologue thereof.

10. (Amended) A composition useful for facilitating bronchoprotection, said composition comprising an activator of a PAR in airway epithelium and at least one **[or more]** pharmaceutically acceptable carriers and/or diluents.

11. (Amended) **[A]** The composition according to claim 10 wherein the PAR is selected from the group consisting of PAR1 **[or]** and PAR2.

12. (Amended) **[A]** The composition according to claim 10 wherein the PAR is PAR2.

13 (Amended) An isolated molecule comprising protease activated receptor (PAR) activity wherein said molecule is **[isolatable]** isolable from airway epithelium and upon activation, said molecule stimulates, induces or otherwise facilitates inhibition of bronchoconstriction and/or inflammation in **[humans and]** animals.

14. (Amended) **[An]** The isolated molecule according to claim 12 wherein the PAR molecule is PAR2.

15. (Amended) A **[recombinant, synthetic or purified, naturally occurring]** molecule comprising protease activated receptor-2 (PAR2) activity wherein **[said molecule in its naturally occurring form is isolatable from airway epithelium and]** upon activation by a PAR2 activating peptide, said molecule stimulates, induces or otherwise facilitates inhibition of bronchoconstriction and/or inflammation in humans and animals.